Aesthetic pharmaceutical company Evolus has announced it is to be the exclusive US distributor of five dermal fillers, currently in late-stage development.
The company is to take over US distribution of dermal filler line Evolysse from Symatese. The first two indications are expected to be launched in 2025, with a third in 2026 and the final two in 2027. The company says the full line will cover a spectrum of facial indications including mid-face, nasolabial folds, lips and eyes.
As a result of this expansion, Evolus has raised its 2028 revenue outlook by $200 million to $700 million.
David Moatazedi, Evolus’ president and chief executive officer, said, “This announcement represents a material step in achieving our goal of transforming Evolus into a multi-product aesthetics company. We are excited to expand our portfolio with Evolysse – a highly competitive filler line. Injectables are the cornerstone of aesthetics, with neurotoxins and dermal fillers as the top two aesthetic procedures in the US. Our customer-centric approach, existing digital infrastructure and distribution platform will power the launch of this innovative filler technology into the hands of our customers and their patients.”
